SLC16A1

Across TCGA pan-cancer cohorts, SLC16A1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC16A1 data layer compared with 28 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SLC16A1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SLC16A1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and UCEC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where SLC16A1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.617	0.863	.001	54	view →
LSCC	DFS	Quartile	III,IV	0.969	0.322	.004	32	view →
PDAC	DFS	Median	III,IV	0.207	0.470	.004	30	view →
UCEC	DFS	Median	III,IV	0.905	0.494	.044	8	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.906	.025	3	view →
LUAD	DFS	Tertile	All	0.924	0.482	.012	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC16A1–CCRCC (DFS)

Open the CCRCC breakdown →